BioWorld

Nov. 17, 2008

Market Woes Reshaping Exec Pay from Both Sides

Executive compensation did not escape the harsh glare of the public spotlight during the recent implosion of the financial service industry. (BioWorld Today) Read More

Pfizer Focus on Stem Cells Could Help Some Biotechs

New Stem Cell Type Shows Value of Sticking Together

HHS: VCs to Play Critical Role in Personalized Medicine

Other News To Note

Clinic Roundup

Earnings Roundup

Financings Roundup

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Heartbeam wins appeal, gains FDA clearance

BioWorld MedTech

Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram...